From viability to cell death: claims with insufficient evidence in high-impact cell culture studies

Basit Öğe Kaydı
dc.authoridCaner Geyik / 0000-0002-8382-2186en_US
dc.authorscopusidCaner Geyik / 36175828200
dc.authorwosidCaner Geyik / JAF-3309-2023
dc.contributor.authorAli Burak, Ă–zkaya
dc.contributor.authorGeyik, Caner
dc.date.accessioned2022-02-28T14:14:00Z
dc.date.available2022-02-28T14:14:00Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Sağlık Bilimleri Enstitüsü, Kanser Biyolojisi ve Farmakolojisi Programıen_US
dc.description.abstractAbstract Background: Reliability of preclinical research is of critical concern. Prior studies have demonstrated the low reproducibility of research results and recommend implementing higher standards to improve overall quality and robustness of research. One understudied aspect of this quality issue is the harmony between the research hypotheses and the experimental design in published work. Methods and findings: In this study we focused on highly cited cell culture studies and investigated whether commonly asserted cell culture claims such as viability, cytotoxicity, proliferation rate, cell death and apoptosis are backed with sufficient experimental evidence or not. We created an open access database containing 280 claims asserted by 103 different high-impact articles as well as the results of this study. Our findings revealed that only 64% of all claims were sufficiently supported by evidence and there were concerning misinterpretations such as considering the results of tetrazolium salt reduction assays as indicators of cell death or apoptosis. Conclusions: Our analysis revealed a discordance between experimental findings and the way they were presented and discussed in the manuscripts. To improve quality of pre-clinical research, we require clear nomenclature by which different cell culture claims are distinctively categorized; materials and methods sections to be written more meticulously; and cell culture methods to be selected and utilized more carefully. In this paper we recommend a nomenclature for selected cell culture claims as well as a methodology for collecting evidence to support those claims.en_US
dc.identifier.citationĂ–zkaya AB, Geyik C. From viability to cell death: Claims with insufficient evidence in high-impact cell culture studies. PLoS One. 2022 Feb 22;17(2):e0250754.en_US
dc.identifier.doi10.1371/journal.pone.0250754en_US
dc.identifier.issue2en_US
dc.identifier.pmid8863264en_US
dc.identifier.scopus2-s2.0-85125153775en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.urihttps://doi.org/10.1371/journal.pone.0250754
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2513
dc.identifier.volume17en_US
dc.identifier.wosWOS:000812552500002en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorGeyik, Caner
dc.language.isoenen_US
dc.relation.ispartofPLoS Oneen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleFrom viability to cell death: claims with insufficient evidence in high-impact cell culture studiesen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
Ä°sim:
10.1371_journal.pone.0250754.pdf
Boyut:
613.51 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Ä°ndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
Ä°sim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
Ä°ndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu